Teva Pharmaceutical Industries Limited
TEVAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeTeva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and. The $45.96B market capitalization puts TEVA squarely in large-cap range for its industry. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Market Cap
$45.96B
Beta
0.82
P/E (TTM)
65.68
P/E (Fwd)
12.76
EPS (TTM)
$0.60
EPS (Fwd)
$3.09
ROE
9.7%
ROA
5.1%
Cash
$3.66B
Total Debt
$16.89B
Free CF
$2.22B
52W Change
101.0%
Annual Financials
Cash vs Debt
Where TEVA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, TEVA finished 19.98% above its 150-day moving average ($34.59) and 21.52% above its 200-day moving average ($34.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TEVA overbought or oversold?
At the October 19, 2026 close, TEVA's RSI(14) was 72.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Teva Pharmaceutical Industries Limited carries $16.89B in total debt against $3.66B in cash reserves — debt is roughly 4.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $2.22B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 9.7% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $14.93B to $17.26B.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Teva Pharmaceutical Industries Limited and its sector.